"Citron's reports are a lot more fun to read than just about anything published by a mainstream Wall Street stock analyst."
-- Bloomberg News

Twitter
October 30, 2014
HomeReportsArchivesContact Us / SuggestionsLegal DisclaimerWho is Citron
 

Questcor in Cover-Up Mode: Deleting Evidence from its Website … BUT Citron Finds the Smoking Gun and Presents it Here for the Federal Trade Commission. Investors please don’t read further — you might find something you don’t like.

Posted in Citron Reports by Stocklemon on the December 3rd, 2013

Over the coming months, Citron Research will release a series of articles on Questcor (NASDAQ:QCOR) intended to shed light on probable issues of interest to the multi-pronged investigation underway by multiple regulatory agencies into numerous aspects of Questcor’s business strategy that political correct-speak would deem “legally challenged”.  These articles will dig deeper into topics such as:

·         The Chronic Disease Fund, and the role it plays in contributing to Questcor’s revenues

·         Medicare billing (it is very dangerous to participate in a scheme to defraud the Federal Government)

·         Insurance reimbursement coding for Acthar

Meanwhile, today’s question is whether Questcor’s Synacthen acquisition is anti-competitive.  The points raised in Citron’s article last week are relevant to the FTC’s inquiry, demonstrating Questcor’s intent to suppress competition by acquiring Synacthen is exposed by their own sell-side analysts.

We are sure that Questcor will now try to posture to the FTC that Synacthen is a completely different drug, arguing that while it has similarities, it cannot be regarded as a replacement for HP Acthar Gel.  This piece of evidence presented below is for the FTC, so shareholders please cover your eyes.  

For the full story you won't find anywhere else, click here!

( Citron as always recommends downloading the PDF for local viewing, and clicking on the links.) 


9 queries in 1.664 seconds